Latest News & Features
Biotechnology
AI and computer-related inventions that use biological data are hot property, but what IP is best to protect them? Lauris Kemp, Claire Irvine, and Susan Keston of HGF explain. 12 June 2023
Big Pharma
Big pharma company picks pan-European venue for next leg of global dispute | IT issues potentially behind new court's low revocation count | Nearly half a million opt-outs registered. 6 June 2023
Big Pharma
Despite one judge’s insistence that the case was “narrow and fact dependent”, GSK v Teva could have wide-reaching implications for generic drugs, biosimilars, and how skinny labels are read, say Chad Landmon, Ross Blau, Gulrukh Haroon of Axinn, Veltrop & Harkrider. 23 May 2023
Africa
Government-led schemes to incentivise patents are leading to delays and prejudice against legitimate applicants. Tyron Grant of Spoor and Fisher explains how South Africa is tackling the problem. 9 May 2023
Plant Varieties
An important post-Brexit deadline for UK holders of Retained EU Plant Variety Rights is approaching, explain Alice Smart and Simon Bradbury of Appleyard Lees. 27 April 2023
Americas
It may not be straightforward but it is possible to obtain protection for valuable combination patents in Brazil, say Lívia Figueiredo and Priscila Kashiwabara of Kasznar Leonardos Intellectual Property. 13 April 2023
Americas
Pinsent Masons and Sterne, Kessler, Goldstein, & Fox consider why the Unified Patent Court, due to open on June 1, 2023, will make Europe a more attractive patent litigation venue for US businesses. 4 April 2023
Americas
As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings. 28 March 2023
Big Pharma
As AbbVie’s multibillion-dollar blockbuster drops over the patent cliff, is it time to tighten up patent and pricing strategies in the US? Sarah Speight investigates. 21 March 2023
Biotechnology
The Pharmaceutical Accountability Foundation has accused the pharma giant of excessively pricing its blockbuster drug, and believes it could influence the regulation of pricing and patent policy for global medicines in the process. 9 March 2023